Abstract
Mbd3, a member of nucleosome remodeling and deacetylase (NuRD) co-repressor complex, was previously identified as an inhibitor for deterministic induced pluripotent stem cell (iPSC) reprogramming, where up to 100% of donor cells successfully complete the process. NuRD can assume multiple mutually exclusive conformations, and it remains unclear whether this deterministic phenotype can be attributed to a specific Mbd3/NuRD subcomplex. Moreover, since complete ablation of Mbd3 blocks somatic cell proliferation, we aimed to explore functionally relevant alternative ways to neutralize Mbd3-dependent NuRD activity. We identify Gatad2a, a NuRD-specific subunit, whose complete deletion specifically disrupts Mbd3/NuRD repressive activity on the pluripotency circuitry during iPSC differentiation and reprogramming without ablating somatic cell proliferation. Inhibition of Gatad2a facilitates deterministic murine iPSC reprogramming within 8 days. We validate a distinct molecular axis, Gatad2a-Chd4-Mbd3, within Mbd3/NuRD as being critical for blocking reestablishment of naive pluripotency and further highlight signaling-dependent and post-translational modifications of Mbd3/NuRD that influence its interactions and assembly. Optimized partial depletion of Mbd3 had been implicated in deterministic reprogramming. Hanna and colleagues now dissect the subcomplex within Mbd3/NuRD that underlies this outcome. Gatad2a is identified as a flexible component that can be entirely ablated without compromising somatic cell proliferation and yet still similarly yields deterministic mouse iPSC formation.
Original language | English |
---|---|
Pages (from-to) | 412-425.e10 |
Journal | Cell Stem Cell |
Volume | 23 |
Issue number | 3 |
DOIs | |
State | Published - 6 Sep 2018 |
Bibliographical note
Funding Information:J.H.H. is supported by a generous gift from Ilana and Pascal Mantoux and research grants from the ERC (ERC-2016-COG-726497; CellNaivety and ERC-2015-PoC-692945; FORMAT), Flight Attendant Medical Research Council (FAMRI), Israel Science Foundation (ISF-ICORE, ISF-NFSC, ISF-INCPM, and ISF-Morasha programs (also to N.N.)), Kamin-Yeda Fund, Minerva Stiftung, the Israel Cancer Research Fund (ICRF) Research Professorship, EMBO Young Investigator Program (EMBO-YIP), Israel MOH, Israel MOST, the Human Frontiers Science Program (HFSP) (RGY0065/2015), the Benoziyo Endowment fund, the New York Stem Cell Foundation (NYSCF), the Helen and Martin Kimmel Institute for Stem Cell Research, the Kimmel Prize by the Weizmann Institute, the Weizmann - U. Michigan Research Program, and the Keckst Center. A.Z. is supported by an EMBO long-term postdoctoral fellowship (ALTF-140-2016). J.H.H. is an NYSCF-Robertson Investigator. We thank the Weizmann Institute management and board for providing critical financial and infrastructural support.
Funding Information:
J.H.H. is supported by a generous gift from Ilana and Pascal Mantoux and research grants from the ERC ( ERC-2016-COG-726497 ; CellNaivety and ERC-2015-PoC-692945 ; FORMAT), Flight Attendant Medical Research Council (FAMRI) , Israel Science Foundation (ISF-ICORE, ISF-NFSC, ISF-INCPM, and ISF-Morasha programs (also to N.N.)), Kamin-Yeda Fund, Minerva Stiftung , the Israel Cancer Research Fund (ICRF) Research Professorship, EMBO Young Investigator Program (EMBO-YIP), Israel MOH , Israel MOST , the Human Frontiers Science Program (HFSP) ( RGY0065/2015 ), the Benoziyo Endowment fund, the New York Stem Cell Foundation (NYSCF) , the Helen and Martin Kimmel Institute for Stem Cell Research , the Kimmel Prize by the Weizmann Institute, the Weizmann - U. Michigan Research Program, and the Keckst Center . A.Z. is supported by an EMBO long-term postdoctoral fellowship (ALTF-140-2016). J.H.H. is an NYSCF-Robertson Investigator. We thank the Weizmann Institute management and board for providing critical financial and infrastructural support.
Publisher Copyright:
© 2018 Elsevier Inc.
Keywords
- CHD4
- Gatad2a
- Mbd3
- NuRD
- P66α
- epigenetics
- iPSCs
- pluripotency
- reprogramming